Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02944500 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Saxenda: Underlying Mechanisms and Clinical Outcomes

StatusActive, Not Recruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary and study completion dates: Jun 2026 to Jun 2027v14
  2. Primary completion date: Dec 2024 to Jun 2026 Completion date: Dec 2025 to Jun 2026v13 Show 1 more changeShow less
    • Completion date: Dec 2025 to Jun 2026
  3. Completion date: Dec 2024 to Dec 2025v12
  4. Primary and study completion dates: Dec 2023 to Dec 2024v11
  5. Primary completion date: Dec 2021 to Dec 2023 Completion date: Dec 2022 to Dec 2023 · Study description expanded, about 31 wordsv10 Show 2 more changesShow less
    • Completion date: Dec 2022 to Dec 2023
    • Study description expanded, about 31 words

    See this version in full on ClinicalTrials.gov ↗

Show 8 earlier versionsHide 8 earlier versions
  1. 2 versions Re-verified since Jun 24, 2020, no change to tracked fieldsv8-v9
  2. Trial status: Recruiting to Active, Not Recruiting Site details revisedv7 Show 1 more changeShow less
    • Site details revised
  3. Primary completion date: Dec 2020 to Dec 2021 Completion date: Dec 2021 to Dec 2022v6 Show 1 more changeShow less
    • Completion date: Dec 2021 to Dec 2022
  4. 2 versions Re-verified since Jan 25, 2017, no change to tracked fieldsv4-v5
  5. Trial status: Not Yet Recruiting to Recruiting Completion date: Dec 2021 · Site details revisedv3 Show 2 more changesShow less
    • Completion date: Dec 2021
    • Site details revised
  6. Interventions: liraglutide (Drug) to Placebo (Other), liraglutide (Drug)v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this protocol is to investigate the effect of treatment with the study drug Liraglutide, a GLP-1 receptor agonist, on centers of the brain that control appetite and food intake.
Trial Details
NCT Number NCT02944500
Lead Sponsor Beth Israel Deaconess Medical Center
Conditions Obesity
Enrollment 28 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov